CPT1A and type 2 diabetes mellitus: Etomoxir, an inhibitor of CPT1a and thus of long chain fatty acid oxidation, increased ECAR in CD3/CD28-stimulated PBMCs from ObNGT but not T2D subjects [27], which is also consistent with the preference of T2D T-cells for non-mitochondrial metabolism in our current study.